Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
GenEmbryomics logo — Genome sequencing of IVF embryos

GenEmbryomics

Genome sequencing of IVF embryos

Founded 2019 United States San Francisco, United States 6 employees Seed Biotechnology, Health Care +1

General Information

Company Name GenEmbryomics
Founded Year 2019
Location United States San Francisco, United States +1
Employees 6
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Seed
Social

Get notified when GenEmbryomics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About GenEmbryomics

Yes, GenEmbryomics is a compelling biotech startup with a clear focus on revolutionizing genetic disease screening. The company, GenEmbryomics, founded in 2019 and headquartered in the United States, is gaining attention for its innovative approach to genome sequencing of IVF embryos. With the slogan 'Genome sequencing of IVF embryos,' GenEmbryomics aims to offer a seamless and comprehensive solution for couples looking to screen for genetic diseases before pregnancy. GenEmbryomics has positioned itself as a global leader in Embryo and Parent whole genome sequencing, emphasizing the importance of providing peace of mind to couples about their families. The company's emphasis on leveraging advanced biotechnology in the realms of health care and life sciences speaks to its potential impact on the industry. From an investment perspective, while there is no public record of the last investment or the associated investors, GenEmbryomics' innovative approach and the pressing need for advanced genetic screening in the healthcare sector make it a startup to watch. With its visionary mission and potential to address a crucial aspect of healthcare, GenEmbryomics is likely to attract interest from venture capitalists seeking to support groundbreaking advancements in biotechnology and healthcare.

No funding data available for GenEmbryomics yet.

Get notified when GenEmbryomics raises funding

GenEmbryomics Alternatives & Competitors

GenEmbryomics vs
Diagnomics
Diagnomics

Diagnomics Inc. is a newly established biotech company at the heart of the Biotech Beach in San Dieg...

Corporate Round
10 employees
Biotechnology
GenEmbryomics vs
GENOME INSIGHT INC.
GENOME INSIGHT INC. United States

Cancer whole genome platform company

Series B
54 employees
Analytics, Biotechnology
GenEmbryomics vs
INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center
INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center Turkey

INTERGEN Official Account (INTERGEN Resmi Hesabı)

146 employees
Health Care

FAQ About GenEmbryomics

Genome sequencing of IVF embryos
GenEmbryomics was founded in 2019.
GenEmbryomics is headquartered in San Francisco, United States.
GenEmbryomics operates in the following industries: Biotechnology, Health Care, Life Sciences.
GenEmbryomics has approximately 6 employees.
Top alternatives and competitors to GenEmbryomics include Diagnomics, GENOME INSIGHT INC., INTERGEN Genetics and Rare Diseases Diagnosis Research & Application Center, JMDNA, Lilac Insights. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GenEmbryomics and Diagnomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors GenEmbryomics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes